Version history

{
  "session_id": "sess_SDA-2026-04-04-frontier-proteomics-1c3dba72_20260412-115413",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Evaluation: Synaptic Proteomic Hypothesis in Early Alzheimer Disease\n\n---\n\n## Overall Framing Assessment\n\nBefore evaluating individual hypotheses, a structural concern must be raised: the research question proposes five distinct proteomic domains, but only one mechanistic hypothesis is presented. This evaluation must assess what exists. The remaining domains—synaptic vesicle proteins, scaffold interactions, RTK signaling, mitochondrial proteins, and APP processing—lack corresponding hypotheses, making the request internally inconsistent. I'll evaluate what is provided and flag what's missing.\n\n---\n\n## Critical Evaluation: Hypothesis 1\n\n### Mechanistic Claim Summary\nCdk5/p25 activation → PSD-95 S561 phosphorylation → disrupted PDZ interactions → recruitment of ubiquitin ligases → ADAM10 degradation → shift from α- to β-secretase APP processing.\n\n---\n\n### 1. Strongest Specific Weakness: Missing Link Between PSD-95 Phosphorylation and ADAM10 Degradation\n\nThe hypothesis proposes a four-step chain from phosphorylated PSD-95 to ADAM10 loss. This is the most mechanistically vulnerable segment. PSD-95 is a synaptic scaffold; for it to directly facilitate ADAM10 degradation would require formation of a ternary complex (phospho-PSD-95 / E3 ligase / ADAM10) that has not been demonstrated in the literature.\n\n**The mechanistic gap:**\n- PSD-95 itself is ubiquitinated by E3 ligases including Mdm2 (via Dmdu-mdm2 in Drosophila) and UBE2A/NAE, but this targets PSD-95 for degradation, not ADAM10.\n- ADAM10 is a transmembrane protease with complex trafficking through the ER, Golgi, and plasma membrane. Its degradation is typically lysosomal or proteasomal and regulated by its own substrates and interacting proteins (e.g., TIP60, LRP1).\n- For PSD-95 S561 phosphorylation to drive ADAM10 degradation, one must explain how a postsynaptic density protein physically interacts with and directs E3 ligase activity toward a presynaptic/perisynaptic membrane protease with no confirmed PSD-95 binding motif.\n\nThe spatial compartmentalization is particularly problematic: ADAM10 processing of APP occurs primarily at the plasma membrane and in the trans-Golgi network, while PSD-95 S561 is presumably postsynaptic. Physical proximity is not established.\n\n---\n\n### 2. Counter-Evidence and Known Complications\n\n**a. Cdk5 activity in early AD is more complex than presented.**\nLiterature suggests Cdk5 activity is dysregulated in AD, but the directionality is context-dependent. In some hAPP/J20 models, Cdk5 activity is actually suppressed early in disease, with p25 accumulation correlating with later stages. Aβ itself can transiently inhibit Cdk5 through calpain activation and p35 cleavage—this creates a negative feedback loop rather than unidirectional activation. The hypothesis assumes Cdk5 hyperactivity drives synaptic dysfunction, but the temporal kinetics in human tissue remain unclear.\n\n**b. PSD-95 S561 is not a well-established pathological phosphorylation site.**\nMost literature on PSD-95 phosphorylation focuses on S295 (CaMKII site) and S397 (PKA/Cdk5). While S561 has been identified in phosphoproteomic screens, its functional validation as a Cdk5 target with pathology-specific significance is limited. A recent phosphoproteomic study of AD human tissue (Wingo et al., 202",
  "tokens_used": "826"
}